nach oben

Erschienen in:

30.01.2022 | COVID-19 | Letter to the Editor Zur Zeit gratis

Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy

Erschienen in: Annals of Nuclear Medicine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

Messenger RNA (mRNA) COVID-19 vaccine is one of the main vaccine types currently used for preventing SARS-CoV-2 infection worldwide. However, its administration can interfere with an FDG PET study since an increased uptake of 18F-FDG can be observed at the vaccine injection site and adjacent regional lymph nodes. The interpretation of PET study in oncologic patients might be impacted especially in head and neck cancer, breast cancer or lymphoma in which supraclavicular and axillary lymph node metastases are suspected. Hence, Advani et al. [1] suggest that FDG PET study should be performed at least 2 weeks after vaccination to reduce the interference of lymphadenopathy causing by vaccination in PET interpretation. …

Advani P, Chumsri S, Pai T, Li Z, Sharma A, Parent E. Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients. Ann Nucl Med. 2021;35(11):1264–9. https://doi.org/10.1007/s12149-021-01675-8.CrossRefPubMedPubMedCentral

Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021;48(6):1854–63. https://doi.org/10.1007/s00259-021-05314-2.CrossRefPubMedPubMedCentral

Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of increased FDG PET/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination. Radiology. 2021;300(3):E345–7. https://doi.org/10.1148/radiol.2021210886.CrossRefPubMed

Cohen D, Hazut Krauthammer S, Wolf I, Even-Sapir E. A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients. Eur J Nucl Med Mol Imaging. 2021;15:1–7. https://doi.org/10.1007/s00259-021-05579-7.CrossRef

Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN, Gallagher KM, Hanna EY, Hicks M, Ilica AT, Mayer EL, Shinagare AB, Yeh R, Mayerhoefer ME, Hricak H, Vargas HA. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. Radiology. 2021;300(2):E323–7. https://doi.org/10.1148/radiol.2021210436.CrossRefPubMed

Titel: Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy
Publikationsdatum: 30.01.2022
Schlagwort: COVID-19
Erschienen in: Annals of Nuclear Medicine / Ausgabe 3/2022
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-021-01712-6

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

Feasibility of 125I-RGD uptake as a marker of angiogenesis after myocardial infarction

A design of forceps-type coincidence radiation detector for intraoperative LN diagnosis: clinical impact estimated from LNs data of 20 esophageal cancer patients

I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response

Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses

Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab